Techniques4 min read

Blueberry Tissue Culture: What One Vaccinium Review Does and Doesn't Tell a Lab

A 2020 open-access review lays out the market and the conventional-propagation problem that make Vaccinium attractive to micropropagators. Its protocol detail is a different matter, and each figure belongs to a study and a genotype.

By xPlant EditorialUpdated 2026-11-15
RedditLinkedIn
Illustration of a blue blueberry-shaped toy character with a leafy crown holding a magnifying glass up to a small green plantlet, beside a bench with a row of lidded glass jars each holding a seedling, an open notebook and a green stem cutting on paper.
A blueberry toy character examines young Vaccinium plantlets on gel, weighing what the review actually supports.Illustration: xPlant Pro.

Field notes

  • The review gives 2018 production of about 149 thousand MT in Canada and 275 thousand MT in the US, so demand for Vaccinium is documented.
  • Conventional propagation is described as time consuming at scale, and seed does not maintain trueness-to-type.
  • Tissue culture can start from node sections or leaves; which suits which genotype is not settled by the review's introduction.
  • Market tonnage and export value are fruit figures, not plantlet costs or acclimatization survival.
  • Any multiplication or rooting number belongs to its study and genotype; keep your own records.

That is the demand backdrop for a lab weighing whether to take Vaccinium on. It is not a protocol, and it is not a price for a plantlet. This piece reads the open-access review in Molecules, by Samir Debnath and Juran Goyali (Agriculture and Agri-Food Canada, St. John's, and Memorial University of Newfoundland), for what it establishes about the crop and where a lab has to go elsewhere. The sections covering media, growth regulators, sterilization, multiplication rates, rooting and acclimatization are in the full text and are not reported here.

What's actually happening

The review covers micropropagation and conventional propagation of blueberries, cranberries and lingonberries, and how each affects morphology and antioxidant properties. Its framing is the fruit and the plant material, not lab economics.

Commercial fruit comes mainly from four sections: Cyanococcus (cluster-fruited blueberries), Oxycoccus (cranberries), Vitis-idea (lingonberries) and Myrtillus (bilberries). Among blueberries, the commercially cultivated species it names are highbush (V. corymbosum), lowbush (V. angustifolium) and rabbiteye.

The conventional route is the bottleneck

The review says nurseries generally propagate blueberries and lingonberries from stem or rhizome material, which it describes as easy but time consuming for large-scale multiplication. Seed is used on a limited scale because it does not maintain trueness-to-type of the donor plant. Cranberries are traditionally propagated with runner cuttings.

The clearest case is lowbush. Extensive plantings have not followed, which the authors attribute to slow establishment and a lack of rhizome production from stem cuttings.

What the review says about tissue culture

It describes micropropagation as able to produce numerous new clones from a single source plant in a short time, all year round, and as useful both for improving existing wild berry fields and for establishing new farms. Those are the authors' characterizations. The portion of the review covered here gives no multiplication rate with a unit, genotype and medium attached.

The abstract also reports that total antioxidant activity was higher in the fruit of in vitro propagated plants than in plants grown ex vivo. That is a fruit-composition finding, and a lab shouldn't read it as a statement about yield, survival or cost.

What it means for growers

The reasoning that holds up is narrow.

The case for clonal material is documented. If seed doesn't hold type and stem or rhizome cuttings are slow, a lab that can supply true-to-type plantlets has a plausible role. For lowbush, the review ties slow establishment and poor rhizome production from stem cuttings to the absence of extensive plantings. That describes a gap in conventional supply. It does not show that a culture-derived plant fills the gap at a price buyers will pay.

The explant question is open for your genotype. Nodes or leaves are both named as starting points. The review's introduction doesn't say which suits which species or cultivar, so that comes from the primary studies and from your own initiation trials.

The market figures are fruit figures. Production tonnage and export value say the crop is large. They don't tell you what a liner sells for, what a plantlet costs to produce, or what share of transplants survive acclimatization.

Nothing here replaces a per-genotype record. Before citing any multiplication rate, rooting percentage or loss figure from this literature, note the study, species, genotype, medium and growth regulators it came from. A result for one genotype is that study's result, not a rule for every lab.

Before you adopt a protocol

Carry the conditions with the number

When you pull a multiplication rate or rooting result from a paper, write down the genotype, the basal medium, the regulators and their concentrations, and the unit. Concentrations and sterilization steps should come from the study's own methods, with its safety context. Your own jars will vary, and transfer losses and acclimatization losses are normal to record rather than hide.

The open question

What does a finished, acclimatized Vaccinium plant cost your lab, with your cultivar, your multiplication rate and your acclimatization losses? The review establishes why the crop is worth asking about. The answer has to come from the protocol tables in the full text, the primary studies they cite, and a few cycles of your own records.

From the bench to the books

Run the lab on records, not memory

Sources

References and credits

  1. In Vitro Propagation and Variation of Antioxidant Properties in Micropropagated Vaccinium Berry Plants—A ReviewOfficial source · Molecules (MDPI), via PubMed Central · Peer-reviewed open-access review (Debnath and Goyali, 2020, CC BY). Used for market figures, species and section background, conventional propagation limits, and explant types. Protocol detail is not reported here.
RedditLinkedIn